Evommune (NYSE:EVMN) Raised to “Strong-Buy” at Clear Str

Evommune (NYSE:EVMN) was upgraded by Clear Str to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other research analysts also recently commented on the company. HC Wainwright reduced their price target on Evommune from $65.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings initiated coverage on shares of Evommune in a research note on Tuesday, February 3rd. They issued a “sell (e)” rating for the company. Cantor Fitzgerald began coverage on shares of Evommune in a report on Monday, December 1st. They set an “overweight” rating for the company. The Goldman Sachs Group upgraded shares of Evommune to a “buy” rating in a research note on Wednesday, January 7th. Finally, Raymond James Financial assumed coverage on shares of Evommune in a research report on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $47.17.

Evommune Trading Down 3.2%

NYSE EVMN opened at $23.32 on Tuesday. The stock’s fifty day moving average price is $23.26. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The firm has a market capitalization of $839.76 million and a PE ratio of -2.89.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Institutional Trading of Evommune

A number of large investors have recently modified their holdings of EVMN. China Universal Asset Management Co. Ltd. bought a new stake in Evommune in the 4th quarter valued at about $34,000. The Manufacturers Life Insurance Company bought a new stake in Evommune during the 4th quarter valued at $179,000. XTX Topco Ltd acquired a new position in Evommune during the 4th quarter worth $321,000. Oxford Asset Management LLP acquired a new stake in Evommune in the fourth quarter worth about $335,000. Finally, State Street Corp bought a new stake in shares of Evommune during the 4th quarter worth about $539,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.